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In this issue of Cell Stem Cell, Kim et al. (2007b) show, by genome-wide single-nucleotide polymor-
phism analysis, that human ES cells claimed to originate from a somatic cell nuclear transfer (SCNT)
embryo are actually parthenogenetic. This now permits an appreciation of the future therapeutic
utility of this type of cell.In science, as with life, the value of
having something is founded on our
ability to assess it. More often than
not, this appreciation is delayed by ei-
ther mis- or preconceptions or the in-
sufficiency of our methods to evaluate
it. So at long last, after much contro-
versy and suspicion, the first human
embryo stem cell line wrongly pro-
claimed to originate from a SCNT
embryo (SCNT-hES-1; see Kennedy,
2006) has now in fact been confirmed
as the world’s first human parthenoge-
netic embryo stem (pES) cell line.
The term ‘‘parthenogenesis’’ has
been used to refer to embryonic devel-
opment of eggs activated artificially
without fertilization. Although entirely
of maternal origin, the genetic consti-
tution of parthenogenetic embryos
can range from aneuploid (n-4n) to eu-
ploid (2n), depending on whether one
attempts to interfere with the meiotic
separation of paired homologous
(Meiosis I) or replicated sister chromo-
somes (Meiosis II). Unlike lower spe-
cies, development of parthenogenetic
placental mammals normally fails in
utero, owing to suspected cell-auton-
omous defects affecting parts of
the embryo proper and the placenta
(Fundele et al., 1990). These defects
correlate with misexpression of genes
normally contributed by the paternal
genome. Despite this, pES cells with
a broad range of differentiation poten-
tial have existed for some time, most
notably in the mouse and nonhuman
primates (Robertson et al., 1983;
Cibelli et al., 2002). Most interest in hu-
man pES cells has centered on their
use as an alternative strategy to
SCNT to yield immune histocompati-ble cells for allogeneic (i.e., between
genetically unrelated individuals) and
even autologous (i.e., within the same
individual) transplantation, the latter
restricted to egg donors. In theory,
the potential genetic homozygosity of
pES cells could facilitate tissue match-
ing for allogeneic transplantation, be-
cause only one of normally two possi-
ble sets of histocompatibility antigens
would be expressed. However, this is
offset by heterozygosity arising during
meiotic DNA recombination between
paired homologous chromosomes in
the immature eggs from which pES
cells would be derived. Until recently,
however, the frequency of this hetero-
zygosity and its distribution was
largely unknown.
Earlier this year in Science, Kim et al.
(2007a) provided the first proof of
principle in the mouse that pES cells
could indeed serve to generate major
histocompatability complex (MHC)-
matched tissues for transplantation.
The same study also offered the first
comprehensive and diagnostic ge-
netic profile of pES cells compared
with ES cells from other sources by
using a genome-wide scan of single
nucleotide polymorhphisms (SNPs).
Importantly, whereas ES cell lines de-
rived from fertilized or SCNT embryos
showed no relationship between fre-
quency of heterozygosity and distance
from centromeres, pES cells did. In
these cells, there was a distinct pattern
with distinctive domains of heterozy-
gosity/homozygosity, reflecting the
occurrence of meiotic recombination.
However, the patterns were also af-
fected by the stage of meiosis that
was interrupted in the creation of theCell Stem Cell 1, Sparthenogenetic embryo (Figure 1).
Notably, the diagnostic pattern of a
pES cell generated by interruption of
the second meiotic division (referred
to in their study as p[MII]ES) consisted
of pericentromeric homozygosity and
increasing heterozygosity as physical
and genetic distance from centro-
meres increased.
In thewake of controversy surround-
ing the origin of SCNT-hES-1, genetic
and epigenetic analyses commis-
sioned to confirm its identity provided
evidence that it could be parthenoge-
netic. Although expression analysis of
imprinted genes and bisulphite se-
quencing supported its maternal prov-
enance—as did DNA fingerprint analy-
sis, which confirmed identity at all 40 of
40 informative markers—all but eight
genes were heterozygous. This fre-
quency of heterozygosity was unantic-
ipated, but its interpretation was ham-
pered by the lack of any substantive
knowledge as to the extent of hetero-
zygosity that would be anticipated af-
ter meiotic recombination and the pre-
dicted interference with karyokinesis
necessary toproduce the resulting em-
bryo. That has all changedwith the cur-
rent report of Kim et al. (2007b) in this
issue of Cell Stem Cell showing that
the SCNT-hES-1 line has the same ge-
netic SNP signature associated with
mouse p(MII)ES cells.
The hallmark of true accomplish-
ment is their independent replication
by others, and reports of human pES
cells are now emerging to this effect.
The derivation of six new human pES
cell lines was first published online in
Cloning and Stem Cells in July of this
year by Revazova et al. (2007). Brevinieptember 2007 ª2007 Elsevier Inc. 243
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generation of two lines at the 2006Key-
stone Symposia on Stem Cells (T. Bre-
vini, personal communication), and
there are strong indications that more
reports will follow. Although it is still
too early to tell, the Revazova article
suggests the efficiency of producing
parthenogenetic blastocysts and pES
cell lines is comparable to that using
fertilized embryos and perhaps more
readily achievable than following
SCNT.
Figure 1. Frequency and Distribution of
Genetic Heterozygosity Assessed Using
a Genome-wide SNP Analysis
Kim et al. (2007a, 2007b) have found that chro-
mosomes in mouse and human ES cells origi-
nating from fertilized or SCNT embryos (mouse
only) show no relationship between frequency
of heterozygosity (black lines) and distance
from centromeres (black dot; [A]). By contrast,
chromosomes from pES cells exhibit distinc-
tive domains of heterozygosity determined by
meiotic DNA recombination in the founding im-
mature egg and which karyokinetic event (Mei-
osis I or II) is interrupted in the creation of the
parthenogenetic embryo. Parthenogenetic ES
cells resulting from interruption of the second
meiotic division (referred to p[MII]ES) possess
pericentromeric homozygosity and increasing
heterozygosity distally (B), with the converse
following interruption of the first meiotic divi-
sion, designated p(MI)ES (C).244 Cell Stem Cell 1, September 2007 ªAlthough we now appreciate the
significance of SCNT-hES-1 and the
feasibility of human pES cells, we
remain a long way from appreciating
their promised utility for cell therapy.
Will they be more subject to a higher
incidence of aneuploidy or greater
genetic instability? One of the six lines
reported by Revazova et al. (2007) is
aneuploid, and the SCNT-hES-1 sub-
line evaluated by Kim et al. (2007b)
appeared to have undergone loss of
chromosomes X and 7with duplication
of the latter. However, aneuploidy and
genetic instability have been reported
in human ES cells from fertilized em-
bryos as well. By virtue of their prove-
nance, pES cells will certainly also be
perturbed epigenetically in as much
as they will lack paternal specific im-
prints. However, the biological signifi-
cance of this is unclear. In the mouse,
the epigenetic state of the ES cell
genome is extremely unstable, but
widespread gene dysregulation still
does not preclude mammalian devel-
opmental potential (Humphereys
et al., 2001). Perhaps, the availability
of human pES cells will now provide
unique opportunities to study the
significance of such dysregulation to
human cell differentiation. Also yet to
be established in a model species
such as the mouse or humans is
whether differentiation and engraft-
ment of pES-derived cells is robust
and whether loss of heterozygosity of
critical genomic regions might disrupt
cell function in engrafted tissues. At
the level of a whole organism, loss
of heterozygosity is understood to
amplify negative genetic components
potentially present in the genotype.2007 Elsevier Inc.Whether this proves to be the case for
cell differentiation could well depend
on the identity of genes residing close
to centromeres that are the most apt
to be homozygous. Of course, as has
been said, ‘‘there are also unknown
unknowns,’’ and one expects these
will come to light with further investiga-
tion. For the time being, however, we
can appreciate the knowledge that
we do have and properly take stock
of the future opportunities that it
provides.
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